Takeda Revamp to Cut Costs, Use AI to Incur ¥150 Billion Charge

Takeda Pharmaceutical Co. expects to book about ¥150 billion ($945 million) in restructuring charges for the fiscal year starting next month Japan’s largest drugmaker overhauls its business to cut costs and embrace new technologies to boost efficiency and growth.

The company, which said it anticipates lower restructuring expenses after next year, will streamline corporate functions and forecast that it will deliver more than ¥200 billion in annual gross savings, it said in a statement Wednesday.